Objective: At this consensus conference, we developed evidenceinformed consensus statements and recommendations on the practice of off-pump coronary artery bypass graft (OPCAB) by systematically reviewing and performing meta-analysis of the randomized controlled trials (RCTs) comparing OPCAB and conventional coronary artery bypass (CCAB). Methods: All RCTs of OPCAB versus CCAB through April 2013 were screened, and 102 relevant RCTs (19,101 patients) were included in a systematic review and meta-analysis (15 RCTs of 9551 high-risk patients; and 87 RCTs of 9550 low-risk patients) in accordance with the Cochrane Collaboration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology. Consensus statements for the risks and benefits of OPCAB surgery in mortality, morbidity, and resource use were developed based on best available evidence.
improves survival, symptoms, and quality of life compared to percutaneous coronary intervention. 1Y5 However, these benefits are tempered by the risk of perioperative mortality, stroke, myocardial infarction (MI), respiratory injury, and renal injury. 6, 7 The use of cardiopulmonary bypass (CPB), cardioplegic cardiac arrest, aortic cannulation, and aortic cross clamping are thought to contribute to this morbidity burden. 8, 9 Off-pump coronary artery bypass (OPCAB) seeks to improve patient outcomes by avoiding morbidity attributable to CPB and aortic manipulation, particularly in selected high-risk patients.
Our previous consensus conference and meta-analysis of limited RCT and non-RCT studies found that OPCAB should be considered in high-risk patients undergoing surgical revascularization to reduce perioperative mortality, morbidity, and resource use, when compared to CCAB (class IIa, level of evidence B). 10, 11 Since then, a growing numbers of large RCTs have been published comparing clinical outcomes in OPCAB versus CCAB. 12Y16 The purpose of this evidence-based consensus statement is to perform a systematic review and to perform meta-analysis of the randomized evidence comparing OPCAB to CCAB, and to update our previous consensus statements of OPCAB and CCAB for coronary revascularization in low-and high-risk surgical patients.
MATERIALS AND METHODS
A 2-day consensus conference was held in Dublin, Ireland, May 26Y27, 2013, under the auspices of The International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS). The conference was conducted according to the American College of Cardiology/American Heart Association (ACC/AHA) standards for the development of clinical practice guidelines as described in previous Innovations consensus conferences. 17 The primary objective was to determine whether OPCAB is superior to CCAB with respect to clinical outcomes and resource-related outcomes, and to determine whether such effects differ across prespecified risk groups and settings. The panel consisted of 12 highly experienced coronary surgeons proficient in both methods, 10 of whom perform primarily OPCAB (J.D.P., S.B., J.B., A.D., F.D.F., T.K., A.L., N.P., M.R., V.Z.) and 3 of whom perform primarily CCAB (M.M., J.B., and J.S.). Conflicts of interest policy with disclosure was applied to the panel in this consensus conference, with the cochair (D.C.) entirely without relationships with industries and the chair (J.P.) only having research funding from industries.
Before the consensus conference, a comprehensive search was undertaken in accordance with the Cochrane Collaboration to identify all published randomized trials of OPCAB versus CCAB, in any language. MEDLINE, Cochrane CENTRAL, EMBASE, Current Contents, DARE, NEED, and INAHTA databases were searched from the date of their inception through April 2013. The processes of comprehensive literature search and systematic review followed the methodologies and policies of the ACC/AHA Task Force on Practice Guidelines [http://www.acc.org/clinical/manual/manual_index.htm], whereas the meta-analysis was conducted in accordance with the Quality of Reporting of Meta-Analyses recommendation. 18 The patient groups examined included low-, medium-, and high-risk populations. Summary data from the systematic review and metaanalyses were presented at the consensus conference (D.C., J.M.). The consensus panel provided evidence and/or expert opinion to formulate statements and recommendations regarding OPCAB surgery in various patient populations. The consensus panel was provided evidence and/or expert opinion to formulate statements and to rate agreement with the recommendations regarding OPCAB surgery in various patient populations. Once consensus was reached for a recommendation with a majority vote, outside of minor style, clarification, or editing revisions, the recommendation was finalized.
The statements were assessed by classes of support and levels of evidence according to the classifications of the ACC/ AHA [http://www.acc.org/clinical/manual/manual_index.htm]. Classes of recommendation were defined as follows:
Class I: Conditions for which there is evidence and/or general agreement that a given procedure or therapy is useful and effective;
Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness or efficacy of performing the procedure or therapy;
Class IIa: Weight of evidence or opinion is in favor of usefulness or efficacy;
Class IIb: Usefulness or efficacy is less well established by evidence or opinion;
Class III: Conditions for which there is evidence and/or general agreement that a procedure or therapy is not useful or effective and in some cases may be harmful.
These recommendations were based on the following levels of evidence (LOE):
Level A: The data were derived from multiple randomized clinical trials;
Level B: The data were derived from a single randomized study or from nonrandomized studies;
Level C: The consensus opinion of experts was the primary source of recommendation.
Inclusion Criteria
To be eligible for this meta-analysis, studies met the following criteria: patients were adults undergoing elective, urgent, or emergent CABG; allocation to OPCAB versus CCAB was randomized; at least one clinically relevant or resourcerelated outcome was reported; studies were published or unpublished, in any language. Studies of robotic surgery and/or combined valve/coronary procedures, and all noncomparative studies were excluded.
End Points
All-cause mortality at 30 days and more than 1 year were the primary end points. Secondary outcomes included postoperative incidence of stroke, cognitive dysfunction, acute MI, recurrent angina, coronary reintervention, need for inotropes, need for intra-aortic balloon pump, atrial fibrillation (AF), renal failure, mediastinitis/sternal wound infection, respiratory infection, need for blood transfusion, re-exploration for bleeding, mechanical ventilation time, ICU length of stay (LOS), hospital LOS, hospital costs, and quality of life (QOL). Postoperative AF, MI, respiratory infection, mediastinitis/wound infection, and cognitive dysfunction were defined according to study authors' definitions. Need for transfusion was defined as the proportion of patients requiring red blood cell transfusion during the intraoperative and postoperative periods combined. Renal dysfunction or failure was defined per study authors'definitions: typically renal dysfunction, a new rise in serum creatinine of more than 50%, or a decline in creatinine clearance of more than 50%; and renal failure, a requirement for dialysis.
Statistical Analysis
Outcomes were analyzed as dichotomous variables, with the exception of duration of ventilation and LOS, which were analyzed as continuous variables when the mean and standard deviation were provided. For dichotomous variables, odds ratios and 95% confidence intervals [OR, 95% confidence interval (CI)] were calculated. For continuous variables, the weighted mean difference [WMD, 95% CI] was calculated.
Heterogeneity was explored using the Q-statistic. Owing to the low power of the Q-statistic, we used a higher threshold of P G 0.10 to suggest statistically significant heterogeneity across trials. In addition to the Q-statistic, the I 2 was calculated to quantify the degree of heterogeneity across trials that could not be attributable to chance alone.
For each outcome, the fixed effect or random effects model was used when the Q-statistic suggested lack or presence of heterogeneity, respectively. Pooled effect estimates and heterogeneity between studies were analyzed by use of Comprehensive MetaAnalysis (version 1.0, Biostat, Englewood, NJ USA, 2002) and RevMan (version 4.2.2, Cochrane Collaboration, Oxford, England, 2003). Other than for the Q-statistic, statistical significance was defined as P G 0.05. All tests of statistical significance were two sided. Whenever possible, data were analyzed by intention-to-treat. To determine whether there was publication bias, the consensus panel visually inspected funnel plots for asymmetry in end point studies to detect any relationship between treatment effect and study size.
Subanalyses for each high-risk group was planned a priori for the following patient risk groups (Table 1) : elderly (age older than 70 years old), obesity (generally, body mass index 930 kg/m 2 , although definitions varied across studies), diabetes, renal failure, aortic disease, left main disease, left ventricular dysfunction, chronic obstructive or other pulmonary disease, urgent/emergent or redo bypass, those requiring conversion from OPCAB to CCAB, and those with a high clinical risk score (eg, EuroSCORE 95 or Parsonnet score 915). In subgroup analyses, the differences in relative size of effect were tested using a W 2 test for interaction or a test for trend.
RESULTS
The initial screen identified 4421 citations of which 186 level A studies were identified after retrieval. One hundred two RCTs met the inclusion criteria, including 15 trials in high-risk patients and 87 trials in low-risk patients.
We compared baseline characteristics of patients in the 102 trials in both high-and low-risk patient populations. The mean age for all patients was 63.5 T 7.9 years in OPCAB and 62.9 T 7.6 in CCAB. Women comprised 21% of both patient cohorts. The mean EuroSCORE ratings in OPCAB versus CCAB populations, reported in a minority of studies, were 3.1 T 1.9 versus 3.1 T 1.9 in low-risk patients and 5.2 T 3.6 and 5.2 T 3.4 in high-risk patients. Left ventricular ejection fractions in OPCAB versus CCAB populations were 59.5 T 11.1 and 59.6 T 13.0 in low-risk patients and 44.1 T 8.7 and 41.9 T 8.7 in high-risk patients.
Outcomes for meta-analysis for primary and secondary end points are shown in Table 2 . Based on these results, we present our 23 consensus statements. Renal Dysfunction, GFR G 60 *One or more of the following risk factors: age 70 years or older; presence of peripheral arterial disease, cerebrovascular disease, or carotid stenosis of 70% or more; or renal insufficiency. Patients 60 to 69 years of age were also eligible if they had 1 or more of the following risk factors: presence of diabetes (requiring an oral hypoglycemic agent, insulin, or both), urgent revascularization (after an acute coronary syndrome), a left ventricular ejection fraction of 35% or less, or a recent history of smoking within 1 year.
CONSENSUS STATEMENTS
†At least 3 of the following criteria: age older than 65 years, high blood pressure, diabetes, serum creatinine 9133 mmol/L, EF G 45%, COPD, unstable angina, CHF, repeat CABG, anemia, and carotid atherosclerosis.
AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; STEMI, ST-elevation myocardial infarction. ; and ventilation time [WMD, j2.9 hour (j3.8, j2.0); P = 0.0001] 14,15,19,20,22,23,25,27,29,32,33,36,39,41,42,46,48,51,52,57,60,63, 65,67,69,71,77,78,84,85,87,88,92,93, 14, 15, 27, 35, 37, 39, 41, 42, 51, 55, 57, 87 This finding was not significantly influenced by heterogeneity (I 2 = 10%) or publication bias (P = 0.99). 23. OPCAB is associated with higher incidence of coronary reintervention (CABG/PCI) than CCAB at 1 year [2.2% vs 1.5%; OR, 1.45 (1.08Y1.92); P = 0.01; LOE A]. 14,15,21,28,29,39,41,42,51,53Y55,64,87 This finding was not significantly influenced by heterogeneity (I 2 = 0%) or publication bias (P = 0.66). The NNT was 105 (51Y582).
DISCUSSION
In the meta-analysis of more than 100 randomized controlled studies, we report that OPCAB compares favorably to CCAB to reduce risks of stroke, renal dysfunction/failure, blood transfusion, respiratory failure, atrial fibrillation, wound infection, ventilation time, and ICU and hospital length of stay. These are important benefits. However, OPCAB may be associated with a reduced number of grafts performed and with reduced graft patency, with increased coronary reintervention at 1 year. Although data are limited, there is a suggestion that OPCAB may be associated with increased mortality at a median follow-up of 5 years. These results will be important for patients and surgeons to balance the risks and benefits of OPCAB versus CCAB for an individual patient.
All-cause mortality was similar at 30 days and 1 year with off-pump compared to on-pump surgery in low-risk patients. The incidence of adverse outcomes, including death, MI, stroke, new renal failure requiring dialysis, bleeding and transfusion start to increase for the on-pump group relative to the off-pump group in higher-risk patients. Consistent with published nonrandomized database studies, 116, 117 a CORONARY (Coronary artery bypass grafting surgery Off oR ON pump revasculARization StudY) Trial subanalysis revealed that some adverse events were less frequent for the on-pump group among low-risk patients but surpassed the rate of adverse events after OPCAB in moderate-and high-risk patients. 118 In CORONARY, investigators randomized 4752 patients in 79 centers in 19 countries to OPCAB or CCAB. The 1-year results demonstrated no significant difference between the 2 techniques for first coprimary outcome of death, stroke, MI, and renal failure requiring dialysis at 30 days and 1 year. There was also no difference in the rate of repeat revascularization, quality of life, or neurocognitive function. Notably, in low-risk patients (EuroSCORE 0Y2), there was a trend toward worse 1-year mortality with off-pump (HR, 1.18), whereas patients at moderate to high risk (EuroSCORE Q3) trended to better outcomes with OPCAB (HR, 0.85; P = 0.11). The authors concluded that it is reasonable to prefer on-pump in low-risk and OPCAB in moderate-to high-risk patients.
One possible interpretation is that among low-risk patients, adverse events related to cardiopulmonary bypass are rare and ''technical adverse events'', such as incomplete revascularization or diminished graft patency related to the technical difficulty of OPCAB, may have a net negative impact on some patient outcomes. Conversely, among higher-risk patients, adverse events related to CPB and aortic manipulation are more common and may outweigh technical adverse events, which may not be increased in higher-risk patients, since most patient comorbidities do not render OPCAB more difficult to perform. This speculative hypothesis offers a possible explanation for the bimodal benefit relationship between OPCAB and CCAB across the spectrum of increasing patient risk profiles reported in the CORONARY trial.
Of the RCTs reported in the literature to date, only six have reported mortality rates beyond 1 year; mean follow-up times range from 3.7 to 5 years. 21, 27, 29, 41, 42 ,56Y58 There were no significant differences in mortality, but 5 trials did show trends toward higher mortality with OPCAB. 21, 29, 57, 58 A large nonrandomized study reported similar long-term risk-adjusted survival up to 10 years after OPCAB and CCAB. 119 Regarding technical details of OPCAB, all 6 studies reporting longer-term mortality rates used commercially available stabilization devices, but only 2 of 6 studies mention selective use of intracoronary shunts and routine use of a humidified CO 2 blower was reported in only 2 trials. 21, 41, 42 Intracoronary shunts are considered important adjuncts to OPCAB used by many contemporary practitioners to maintain some blood flow in the distal circulation during construction of coronary anastomoses and to prevent inadvertent suturing of the back wall of the coronary artery. Similarly, a blower improves visualization of the arteriotomy and is critical for accurate anastomotic construction during OPCAB. Finally, intraoperative graft flow assessment is important to ensure complete and precise revascularization. In current practice, such devices are used routinely. Techniques and facilitating devices for OPCAB have evolved and improved since the performance of many of the RCTs, which have reported long-term follow-up. Thus, generalizing those outcomes to modern OPCAB practice should be tempered by this knowledge.
Surgeon experience is an important issue in the comparison of alternative surgical techniques (Table 3 ). In 3 of the 6 trials with longer-term follow-up, sufficient information was presented regarding the learning curve and experience of the operating surgeons. 16, 120, 121 In the Best Bypass Surgery Trial, all surgeons performed at least 50% of their CABG procedures off-pump for more than 2 years. 57 In the SMART (Surgical Management of Arterial Revascularization Therapies) Trial, all procedures were performed by a single experienced OPCAB surgeon who routinely performs more than 95% of CABG off pump. 41 In the other multicenter or multisurgeon trials, specific information is lacking regarding the experience level of the operating surgeons. No detail is available on the postoperative medical management of the patients in these 6 studies. Thus, it is unclear whether differences in short-term or long-term postoperative medication may have influenced patient outcomes.
The findings of this consensus statement will be useful for design of future prospective randomized trials comparing OPCAB to CCAB. First, as OPCAB is highly prevalent in Asia 122 and South America, 123 an RCT should be multicenter and international, and global patient recruitment is desirable. Second, the study team should be interdisciplinary, including superspecialized coronary surgeons, general cardiac surgeons, interventional cardiologists, and general cardiologists. Third, the operators should be adequately experienced to have passed well beyond the initial learning curve for OPCAB. This may require an experience well in excess of 200 OPCAB cases and must include a large number of cases in which off-pump grafting of the lateral wall is successfully accomplished. If centers exclusively or predominantly perform either OPCAB or CCAB, performing the alternative operation may be heavily biased. Participation of balanced centers would therefore be mandatory. Furthermore, concerning surgical methodology, a new trial should apply all current techniques and technologies for both methods. In OPCAB, this includes latest generation exposure devices, stabilizers, and clampless proximal anastomotic devices. It would be important to have adjunct technology such as intracoronary shunts and the mister blower available. Intraoperative transit-time flow measurement assessments should be a routine part of quality control in CABG. Perhaps most importantly, new studies should have a standardized approach to manipulation of the ascending aorta. Epiaortic ultrasound should be routinely used. Side-biting aortic clamping is a known risk factor for perioperative embolic events, and every effort should be made to use no-touch aortic technique or clampless proximal anastomotic devices. 124 Fifth, any new trial should include standardized postoperative antiplatelet and statin treatment. In OPCAB, the application of clopidogrel in addition to aspirin may decrease the likelihood of early postoperative graft thrombosis and reduce long-term adverse events. 125 Finally, a new trial should have hard clinical outcome parameters as the primary end point. Inclusion of midterm survival and freedom from major adverse events between 1 and 5 postoperative years is important to address concern that OPCAB may lead to incomplete revascularization and subsequently to a decrement in long-term patient outcomes.
There are some important limitations to this work. This was a study-level meta-analysis, and as such, we were only able to provide analysis on data that were included in individual publications. Moreover, the study of OPCAB continues and the Randomization was stratified according to the surgeon, so that both surgeons performed similar numbers of OPCAB and CCAB. OPCAB had been started at this center 2 years before the study, and during this time, 98/753 isolated CABGs (13%) were OPCAB list of trials that can be included in this meta-analysis must be limited to a defined time period. Many RCTs provided limited information to assess the experience level of surgeons with the 2 techniques being compared. When such information was provided, experience was often asymmetrical, with surgeons having greater experience with CCAB than with OPCAB. Often, surgeons had performed a small minority of their CABG cases by OPCAB before initiation of patient enrollment in the randomized trials, as evidenced by a significantly higher OPCAB-to-CCAB conversion rate than that reported in The Society of Thoracic Surgeons Adult Cardiac Surgery Database. 126 This asymmetry of surgeon experience and expertise with the 2 alternative surgical techniques being compared is a fundamental limitation of the body of literature from which this meta-analysis was performed. Enrollment of highrisk patients in randomized trials is challenging on multiple levels. Most RCTs comparing OPCAB and CCAB enrolled relatively low-risk patients in whom outcomes with CCAB were expected to be excellent. Many retrospective series and database analyses have suggested that it is higher-risk patients who may benefit most from avoidance of cardiopulmonary bypass. Thus, comparing outcomes between OPCAB and CCAB among low-risk patient cohorts may systematically bias such trials against OPCAB. The generalizability of these trials is therefore limited.
CONCLUSIONS
Rigorous systematic review and meta-analysis of RCTs (level of evidence A) in high-risk and low-risk patients allow several firm recommendations to be made in this Consensus Conference. When compared to CCAB in patients undergoing surgical coronary revascularization, it is reasonable to perform OPCAB to reduce risk of stroke (class IIa, LOE A), renal dysfunction/failure (class IIa, LOE A), blood transfusion (class I, LOE A), respiratory failure (class I, LOE A), development of AF (class I, LOE A), wound infection (class I, LOE A), and to reduce ventilation times as well as ICU and hospital LOS (class I, LOE A). However, OPCAB may be associated with the risks of reduced number of grafts performed (class I, LOE A), reduced graft patency (class IIa, LOE A), increased coronary reintervention at 1 year and beyond (class IIa, LOE A), and increased mortality at a median follow-up of 5 years (class IIb, LOE A). The apparent bimodal relationship between patient risk factors and the relative benefit of OPCAB versus CCAB warrants further study. Surgeon experience may play a more critical role in achieving optimal complete and precise revascularization during OPCAB than CCAB. This review of the literature sounds a cautionary note indicating that sacrificing completeness or precision of revascularization to avoid cardiopulmonary bypass may lead to compromise of longer-term patient outcomes.
